Mitochondrial translocator protein (TSPO) ligands prevent doxorubicin-induced mechanical dysfunction and cell death in isolated cardiomyocytes

Mitochondrion

Volumn 13, Issue 6, 2013, Pages 688-697

  de Tassigny, Alexandra d'Anglemont ^a,b   Assaly, Rana ^a,b   Schaller, Sophie ^c   Pruss, Rebecca M ^c   Berdeaux, Alain ^a,b   Morin, Didier ^a,b  

^a INSERM U955   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c Trophos SA   (France)

Author keywords

Cardiomyocytes; Doxorubicin; Mitochondria; Permeability transition pore; ROS; TSPO ligands

Indexed keywords

4' CHLORODIAZEPAM; CALCIUM ION; DOXORUBICIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL TRANSLOCATOR PROTEIN LIGAND; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; TRO 40303; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CARDIOTOXICITY; CELL DEATH; CELL ISOLATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOMERE LENGTH;

1,2-BIS(O-AMINOPHENOXY)ETHANE-N,N,N′,N′-TETRAACETIC ACID; 2,7-DICHLORODIHYDROFLUORESCEIN-DIACETATE; 4′-CHLORODIAZEPAM; BAPTA; CARDIOMYOCYTES; CDZ; COBALT CHLORIDE; COCL(2); CSA; CYCLOSPORIN A; DCF; DCFH-DA; DICHLOROFLUORESCEIN; DOXORUBICIN; HYDROXYL RADICAL; IMAC; INNER MEMBRANE ANION CHANNEL; MITOCHONDRIA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MPTP; OH; PERMEABILITY TRANSITION PORE; PI; PROPIDIUM IODIDE; REACTIVE OXYGEN SPECIES; ROS; TRANSLOCATOR PROTEIN; TSPO; TSPO LIGANDS;

ANIMALS; CARRIER PROTEINS; CELL DEATH; DOXORUBICIN; LIGANDS; MICE; MICE, KNOCKOUT; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES;

EID: 84886439847     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2013.10.001     Document Type: Article

References (60)

1. Akar F.G., Aon M.A., Tomaselli G.F., O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J. Clin. Invest. 2005, 115:3527-3535.
2. Andersson D.C., Fauconnier J., Yamada T., Lacampagne A., Zhang S.J., Katz A., et al. Mitochondrial production of reactive oxygen species contributes to the beta-adrenergic stimulation of mouse cardiomyocytes. J. Physiol. 2011, 589:1791-1801.
3. Assaly R., de Tassigny A., Paradis S., Jacquin S., Berdeaux A., Morin D. Oxidative stress, mitochondrial permeability transition pore opening and cell death during hypoxia-reoxygenation in adult cardiomyocytes. Eur. J. Pharmacol. 2012, 675:6-14.
4. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
5. Brown K.A., Blow A.J., Weiss R.M., Stewart J.A. Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am. Heart J. 1989, 118:979-982.
6. Campbell D.L., Stamler J.S., Strauss H.C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J. Gen. Physiol. 1996, 108:277-293.
7. +)-induced permeability transition and oxidative damage. Free Radic. Biol. Med. 2008, 45:1395-1402.
8. Childs A.C., Phaneuf S.L., Dirks A.J., Phillips T., Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 2002, 62:4592-4598.
9. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 1986, 261:3060-3067.
10. Delpy E., Hatem S.N., Andrieu N., de Vaumas C., Henaff M., Rucker-Martin C., et al. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc. Res. 1999, 43:398-407.
11. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 1986, 261:3068-3074.
12. Ferreira A.L., Matsubara L.S., Matsubara B.B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6:278-281.
13. Gavish M., Bachman I., Shoukrun R., Katz Y., Veenman L., Weisinger G., et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 1999, 51:629-650.
14. Gutierrez P.L. The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: a review. Free Radic. Biol. Med. 2000, 29:263-275.
15. Halestrap A.P. What is the mitochondrial permeability transition pore?. J. Mol. Cell. Cardiol. 2009, 46:821-831.
16. Horstkotte J., Perisic T., Schneider M., Lange P., Schroeder M., Kiermayer C., et al. Mitochondrial thioredoxin reductase is essential for early postischemic myocardial protection. Circulation 2011, 124:2892-2902.
17. Javadov S., Karmazyn M., Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J. Pharmacol. Exp. Ther. 2009, 330:670-678.
18. Johnson M.D., Wang J.K., Morgan J.I., Spector S. Downregulation of [3H]Ro5-4864 binding sites after exposure to peripheral-type benzodiazepines in vitro. J. Pharmacol. Exp. Ther. 1986, 238:855-859.
19. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 2001, 276:47266-47276.
20. Kalivendi S.V., Konorev E.A., Cunningham S., Vanamala S.K., Kaji E.H., Joseph J., et al. Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem. J. 2005, 389:527-539.
21. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 2002, 234-235:119-124.
22. 2+ transients in rat ventricular myocytes. Circulation 2002, 105:2666-2671.
23. Keefe D.L. Anthracycline-induced cardiomyopathy. Semin. Oncol. 2001, 28:2-7.
24. Kim S.J., Iizuka K., Kelly R.A., Geng Y.J., Bishop S.P., Yang G., et al. An alpha-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes. Am. J. Physiol. 1999, 276:H1780-H1787.
25. Lacapere J.J., Delavoie F., Li H., Peranzi G., Maccario J., Papadopoulos V., et al. Structural and functional study of reconstituted peripheral benzodiazepine receptor. Biochem. Biophys. Res. Commun. 2001, 284:536-541.
26. Lebrecht D., Geist A., Ketelsen U.P., Haberstroh J., Setzer B., Walker U.A. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br. J. Pharmacol. 2007, 151:771-778.
27. Leducq N., Bono F., Sulpice T., Vin V., Janiak P., Fur G.L., et al. Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J. Pharmacol. Exp. Ther. 2003, 306:828-837.
28. Leung A.W., Halestrap A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim. Biophys. Acta 2008, 1777:946-952.
29. Li B., Chauvin C., De Paulis D., De Oliveira F., Gharib A., Vial G., et al. Inhibition of complex I regulates the mitochondrial permeability transition through a phosphate-sensitive inhibitory site masked by cyclophilin D. Biochim. Biophys. Acta 2012, 1817:1628-1634.
30. Lim C.C., Zuppinger C., Guo X., Kuster G.M., Helmes M., Eppenberger H.M., et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 2004, 279:8290-8299.
31. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 1991, 324:808-815.
32. Mimnaugh E.G., Trush M.A., Bhatnagar M., Gram T.E. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol. 1985, 34:847-856.
33. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
34. Montaigne D., Marechal X., Baccouch R., Modine T., Preau S., Zannis K., et al. Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicol. Appl. Pharmacol. 2010, 244:300-307.
35. Morin D., Assaly R., Paradis S., Berdeaux A. Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr. Med. Chem. 2009, 16:4382-4398.
36. Obame F.N., Zini R., Souktani R., Berdeaux A., Morin D. Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J. Pharmacol. Exp. Ther. 2007, 323:336-345.
37. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990, 4:3076-3086.
38. Ovize M., Baxter G.F., Di Lisa F., Ferdinandy P., Garcia-Dorado D., Hausenloy D.J., et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc. Res. 2010, 87:406-423.
39. Papadopoulos V., Mukhin A.G., Costa E., Krueger K.E. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J. Biol. Chem. 1990, 265:3772-3779.
40. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J.J., Lindemann P., et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27:402-409.
41. Petronilli V., Miotto G., Canton M., Brini M., Colonna R., Bernardi P., et al. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys. J. 1999, 76:725-734.
42. Sawyer D.B., Fukazawa R., Arstall M.A., Kelly R.A. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 1999, 84:257-265.
43. Schaller S., Paradis S., Ngoh G.A., Assaly R., Buisson B., Drouot C., et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J. Pharmacol. Exp. Ther. 2010, 333:696-706.
44. Schwartz R.G., McKenzie W.B., Alexander J., Sager P., D'Souza A., Manatunga A., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med. 1987, 82:1109-1118.
45. Shadle S.E., Bammel B.P., Cusack B.J., Knighton R.A., Olson S.J., Mushlin P.S., et al. Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem. Pharmacol. 2000, 60:1435-1444.
46. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
47. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339:900-905.
48. Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., Murphy M.L. Cardiac toxicity 4 to 20years after completing anthracycline therapy. JAMA 1991, 266:1672-1677.
49. Thollon C., Iliou J.P., Cambarrat C., Robin F., Vilaine J.P. Nature of the cardiomyocyte injury induced by lipid hydroperoxides. Cardiovasc. Res. 1995, 30:648-655.
50. Timolati F., Ott D., Pentassuglia L., Giraud M.N., Perriard J.C., Suter T.M., et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 41:845-854.
51. Tokarska-Schlattner M., Zaugg M., da Silva R., Lucchinetti E., Schaub M.C., Wallimann T., et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H37-H47.
52. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J. Mol. Cell. Cardiol. 2006, 41:389-405.
53. Tsang W.P., Chau S.P., Kong S.K., Fung K.P., Kwok T.T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci. 2003, 73:2047-2058.
54. Umemoto S., Tanaka M., Kawahara S., Kubo M., Umeji K., Hashimoto R., et al. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens. Res. 2004, 27:877-885.
55. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. 2003, 93:105-115.
56. Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc. Toxicol. 2007, 7:101-107.
57. Wang Y.X., Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ. Res. 1995, 76:645-653.
58. Xiao J., Liang D., Zhang H., Liu Y., Li F., Chen Y.H. 4'-Chlorodiazepam, a translocator protein (18kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats. Exp. Biol. Med. 2010, 235:478-486.
59. Zoratti M., Szabo I. The mitochondrial permeability transition. Biochim. Biophys. Acta 1995, 1241:139-176.
60. Zorov D.B., Juhaszova M., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc. Res. 2009, 83:213-225.